Literature DB >> 20726987

Ibuprofen is a non-competitive inhibitor of the peptide transporter hPEPT1 (SLC15A1): possible interactions between hPEPT1 substrates and ibuprofen.

Diana Højmark Omkvist1, Birger Brodin, Carsten Uhd Nielsen.   

Abstract

BACKGROUND AND
PURPOSE: Recently, we identified etodolac as a possible ligand for the human intestinal proton-couple peptide transporter (hPEPT1). This raised the possibility that other non-steroidal anti-inflammatory drugs, and especially ibuprofen, could also interact with hPEPT1. Here, we have assessed the interactions of ibuprofen with hPEPT1. EXPERIMENTAL APPROACH: The uptake of [(14)C]Gly-Sar, [(3)H]Ibuprofen and other radio-labelled compounds were investigated in Madin-Darby canine kidney cells (MDCK)/hPEPT1, MDCK/Mock, LLC-PK(1) or Caco-2 cells. The transepithelial transport of ibuprofen and hPEPT1 substrates was investigated in Caco-2 cell monolayers. KEY
RESULTS: Ibuprofen concentration dependently inhibited hPEPT1-mediated uptake of Gly-Sar in MDCK/hPEPT1 cells (K(i)(app) = 0.4 mM) but uptake of ibuprofen in Caco-2 cells and MDCK/hPEPT1 cells was not inhibited by hPEPT1 substrates. The maximum uptake rate for Gly-Sar uptake was reduced from 522 pmol·min(-1)·cm(-2) to 181 pmol·min(-1)·cm(-2) and 78 pmol·min(-1)·cm(-2) in the presence of 0.5 mM and 1 mM ibuprofen, respectively. The interaction between ibuprofen and hPEPT1 was thus non-competitive. In LLC-PK1 cells, ibuprofen (1 mM) did not influence the transporter-mediated uptake of glycine or α-methyl-D-glycopyranoside. In Caco-2 cell monolayers the absorptive transport of δ-aminolevulinic acid was reduced by 23% and 48% by ibuprofen (1 and 10 mM), respectively. Likewise the transport of Gly-Sar was reduced by 23% in the presence of ibuprofen (1 mM). CONCLUSIONS AND IMPLICATIONS: Ibuprofen is a non-competitive inhibitor of hPEPT1. As ibuprofen reduced the transepithelial transport of δ-aminolevulinic acid, drug-drug interactions between ibuprofen and hPEPT1 drug substrates at their site of absorption are possible if administered together.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20726987      PMCID: PMC3010583          DOI: 10.1111/j.1476-5381.2010.01000.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Characterization of methotrexate transport and its drug interactions with human organic anion transporters.

Authors:  Michio Takeda; Suparat Khamdang; Shinichi Narikawa; Hiroaki Kimura; Makoto Hosoyamada; Seok Ho Cha; Takashi Sekine; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

2.  Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).

Authors:  Ailan Guo; William Marinaro; Peidi Hu; Patrick J Sinko
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

3.  Interaction of human organic anion transporters with various cephalosporin antibiotics.

Authors:  Michio Takeda; Ellappan Babu; Shinichi Narikawa; Hitoshi Endou
Journal:  Eur J Pharmacol       Date:  2002-03-08       Impact factor: 4.432

4.  Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line.

Authors:  Carsten Uhd Nielsen; Claudiu T Supuran; Andrea Scozzafava; Sven Frokjaer; Bente Steffansen; Birger Brodin
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

5.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.

Authors:  S H Cha; T Sekine; J I Fukushima ; Y Kanai; Y Kobayashi; T Goya; H Endou
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

6.  Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.

Authors:  Yoshihisa Shitara; Daisuke Sugiyama; Hiroyuki Kusuhara; Yukio Kato; Takaaki Abe; Peter J Meier; Tomoo Itoh; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

7.  Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs.

Authors:  Suparat Khamdang; Michio Takeda; Rie Noshiro; Shinichi Narikawa; Atsushi Enomoto; Naohiko Anzai; Pawinee Piyachaturawat; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

8.  Differential recognition of ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2.

Authors:  T Zhu; X Z Chen; A Steel; M A Hediger; D E Smith
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

9.  Functional characterization of the mouse organic-anion-transporting polypeptide 2.

Authors:  Jessica E van Montfoort; Thomas E Schmid; Ilse-Dore Adler; Peter J Meier; Bruno Hagenbuch
Journal:  Biochim Biophys Acta       Date:  2002-08-19

10.  Kinetics and mechanism of in vitro uptake of amino-beta-lactam antibiotics by rat small intestine and relation to the intact-peptide transport system.

Authors:  E Nakashima; A Tsuji; H Mizuo; T Yamana
Journal:  Biochem Pharmacol       Date:  1984-11-01       Impact factor: 5.858

View more
  7 in total

1.  PharmGKB summary: ibuprofen pathways.

Authors:  Liudmila L Mazaleuskaya; Katherine N Theken; Li Gong; Caroline F Thorn; Garret A FitzGerald; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

2.  Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro.

Authors:  C U Nielsen; S Frølund; S Abdulhadi; H Sari; L Langthaler; M K Nøhr; M A Kall; B Brodin; R Holm
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.

Authors:  Amit A Somani; Kirstin Thelen; Songmao Zheng; Mirjam N Trame; Katrin Coboeken; Michaela Meyer; Katrin Schnizler; Ibrahim Ince; Stefan Willmann; Stephan Schmidt
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

4.  Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines.

Authors:  Zhiying Wang; Dhananjay Pal; Ashaben Patel; Deep Kwatra; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-12-20       Impact factor: 5.875

5.  Toward Xeno-Free Differentiation of Human Induced Pluripotent Stem Cell-Derived Small Intestinal Epithelial Cells.

Authors:  Jaakko Saari; Fatima Siddique; Sanna Korpela; Elina Mäntylä; Teemu O Ihalainen; Katri Kaukinen; Katriina Aalto-Setälä; Katri Lindfors; Kati Juuti-Uusitalo
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

6.  Oral Ibuprofen Interferes with Cellular Healing Responses in a Murine Model of Achilles Tendinopathy.

Authors:  Adam Bittermann; Shuguang Gao; Sabah Rezvani; Jun Li; Katie J Sikes; John Sandy; Vincent Wang; Simon Lee; George Holmes; Johnny Lin; Anna Plaas
Journal:  J Musculoskelet Disord Treat       Date:  2018-05-21

7.  Unveil the Anticancer Potential of Limomene Based Therapeutic Deep Eutectic Solvents.

Authors:  Carolina V Pereira; Joana M Silva; Liliana Rodrigues; Rui L Reis; Alexandre Paiva; Ana Rita C Duarte; Ana Matias
Journal:  Sci Rep       Date:  2019-10-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.